Using Monoclonal Antibody D612 to Identify Colon Cancer Metastases
Author Information
Author(s): M. Mottolese, I. Venturo, G. Digiesi, R. Perrone Donnorso, A. Bigotti, R. Muraro, A. Aluffi, P.G. Natali
Primary Institution: National Cancer Institute 'Regina Elena'
Hypothesis
Can monoclonal antibody D612 improve the diagnosis of colon-rectum carcinoma metastases?
Conclusion
Monoclonal antibody D612 significantly improves the accuracy of diagnosing colon-rectum carcinoma metastases.
Supporting Evidence
- MoAb D612 correlated with correct diagnosis in 92.8% of cases.
- Immunocytochemical methods improved diagnostic accuracy for colon-rectum cancer.
- MoAb D612 was negative in 95% of cases for other cancer types.
Takeaway
Researchers used a special antibody to help doctors figure out if cancer in the body started in the colon or rectum, and it worked really well.
Methodology
The study involved 102 patients and used immunocytochemical tests with monoclonal antibody D612 on effusions and fine needle aspirates.
Potential Biases
Potential bias in patient selection and the interpretation of immunocytochemical results.
Limitations
The study may not account for all types of cancers and relies on the specificity of the antibodies used.
Participant Demographics
Patients included 12 with metastatic effusions, 16 with masses post-colon cancer, 50 with unknown origin effusions, and 24 with masses without a history of neoplasia.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website